Tolcapone
- Generic Name
- Tolcapone
- Brand Names
- Tasmar
- Drug Type
- Small Molecule
- Chemical Formula
- C14H11NO5
- CAS Number
- 134308-13-7
- Unique Ingredient Identifier
- CIF6334OLY
- Background
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
- Indication
Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.
- Associated Conditions
- Idiopathic Parkinson's Disease
- Associated Therapies
- -
Clinical Trial of Tolcapone for Cognition in Schizophrenia
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 210
- Registration Number
- NCT00044083
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Assessment of Potential Interactions Between Cocaine and Tolcapone - 1
- Conditions
- First Posted Date
- 2002-04-08
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 16
- Registration Number
- NCT00033059
- Locations
- 🇺🇸
UCLA Integrated Substance Abuse Program, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.